Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(12):1715–1720. doi: 10.1038/bjc.1997.294

Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide.

E Marshall 1, L B Woolford 1, B I Lord 1
PMCID: PMC2223621  PMID: 9192972

Abstract

Macrophage inflammatory protein 1alpha (MIP-1alpha) inhibits haemopoietic stem cell proliferation. This property has been exploited in a murine chemotherapy model and has been shown to ameliorate cytotoxic-induced myelosuppression after S-phase-specific cytotoxic therapy. We have now shown that BB-10010, a stable mutant of MIP-1alpha, (a) is more effective when administered as a continuous infusion than when bolus injected and (b), when administered via a 7-day infusion during and after cyclophosphamide treatment, results in an earlier recovery of leucocyte numbers. This effect was accompanied by progenitor cell mobilization into the peripheral blood and included primitive cells with marrow-repopulating ability (MRA). Maximal mobilization and recovery of leucocytes occurred when MIP-1alpha was combined with granulocyte colony-stimulating factor (G-CSF) therapy. The findings suggest that MIP1-alpha used alone or in combination with G-CSF may allow delivery of a greater chemotherapy dose intensity as a consequence of both accelerated leucocyte recovery and maintenance of high-quality mobilized progenitor cells for harvesting and peripheral blood stem cell transplantation.

Full text

PDF
1715

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dunlop D. J., Wright E. G., Lorimore S., Graham G. J., Holyoake T., Kerr D. J., Wolpe S. D., Pragnell I. B. Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo. Blood. 1992 May 1;79(9):2221–2225. [PubMed] [Google Scholar]
  2. Graham G. J., Wright E. G., Hewick R., Wolpe S. D., Wilkie N. M., Donaldson D., Lorimore S., Pragnell I. B. Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature. 1990 Mar 29;344(6265):442–444. doi: 10.1038/344442a0. [DOI] [PubMed] [Google Scholar]
  3. Hunter M. G., Bawden L., Brotherton D., Craig S., Cribbes S., Czaplewski L. G., Dexter T. M., Drummond A. H., Gearing A. H., Heyworth C. M. BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties. Blood. 1995 Dec 15;86(12):4400–4408. [PubMed] [Google Scholar]
  4. Jagels M. A., Hugli T. E. Neutrophil chemotactic factors promote leukocytosis. A common mechanism for cellular recruitment from bone marrow. J Immunol. 1992 Feb 15;148(4):1119–1128. [PubMed] [Google Scholar]
  5. Keller J. R., Bartelmez S. H., Sitnicka E., Ruscetti F. W., Ortiz M., Gooya J. M., Jacobsen S. E. Distinct and overlapping direct effects of macrophage inflammatory protein-1 alpha and transforming growth factor beta on hematopoietic progenitor/stem cell growth. Blood. 1994 Oct 1;84(7):2175–2181. [PubMed] [Google Scholar]
  6. Laterveer L., Lindley I. J., Hamilton M. S., Willemze R., Fibbe W. E. Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood. 1995 Apr 15;85(8):2269–2275. [PubMed] [Google Scholar]
  7. Lord B. I., Dexter T. M., Clements J. M., Hunter M. A., Gearing A. J. Macrophage-inflammatory protein protects multipotent hematopoietic cells from the cytotoxic effects of hydroxyurea in vivo. Blood. 1992 May 15;79(10):2605–2609. [PubMed] [Google Scholar]
  8. Lord B. I. MIP-1 alpha increases the self-renewal capacity of the hemopoietic spleen-colony-forming cells following hydroxyurea treatment in vivo. Growth Factors. 1995;12(2):145–149. doi: 10.3109/08977199509028960. [DOI] [PubMed] [Google Scholar]
  9. Lord B. I., Marshall E., Woolford L. B., Hunter M. G. BB-10010/MIP-1 alpha in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation. Br J Cancer. 1996 Oct;74(7):1017–1022. doi: 10.1038/bjc.1996.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lord B. I., Mori K. J., Wright E. G., Lajtha L. G. Inhibitor of stem cell proliferation in normal bone marrow. Br J Haematol. 1976 Nov;34(3):441–445. doi: 10.1111/j.1365-2141.1976.tb03590.x. [DOI] [PubMed] [Google Scholar]
  11. Lord B. I., Woolford L. B., Wood L. M., Czaplewski L. G., McCourt M., Hunter M. G., Edwards R. M. Mobilization of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 alpha. Blood. 1995 Jun 15;85(12):3412–3415. [PubMed] [Google Scholar]
  12. Molineux G., Xu C., Hendry J., Testa N. G. A cellular analysis of long-term haematopoietic damage in mice after repeated treatment with cyclophosphamide. Cancer Chemother Pharmacol. 1986;18(1):11–16. doi: 10.1007/BF00253055. [DOI] [PubMed] [Google Scholar]
  13. Oppenheim J. J., Zachariae C. O., Mukaida N., Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol. 1991;9:617–648. doi: 10.1146/annurev.iy.09.040191.003153. [DOI] [PubMed] [Google Scholar]
  14. Passos-Coelho J. L., Braine H. G., Davis J. M., Huelskamp A. M., Schepers K. G., Ohly K., Clarke B., Wright S. K., Noga S. J., Davidson N. E. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol. 1995 Mar;13(3):705–714. doi: 10.1200/JCO.1995.13.3.705. [DOI] [PubMed] [Google Scholar]
  15. Rot A., Krieger M., Brunner T., Bischoff S. C., Schall T. J., Dahinden C. A. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med. 1992 Dec 1;176(6):1489–1495. doi: 10.1084/jem.176.6.1489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Schall T. J., Bacon K., Camp R. D., Kaspari J. W., Goeddel D. V. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med. 1993 Jun 1;177(6):1821–1826. doi: 10.1084/jem.177.6.1821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wang J. M., Sherry B., Fivash M. J., Kelvin D. J., Oppenheim J. J. Human recombinant macrophage inflammatory protein-1 alpha and -beta and monocyte chemotactic and activating factor utilize common and unique receptors on human monocytes. J Immunol. 1993 Apr 1;150(7):3022–3029. [PubMed] [Google Scholar]
  18. Wolpe S. D., Cerami A. Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J. 1989 Dec;3(14):2565–2573. doi: 10.1096/fasebj.3.14.2687068. [DOI] [PubMed] [Google Scholar]
  19. Wolpe S. D., Davatelis G., Sherry B., Beutler B., Hesse D. G., Nguyen H. T., Moldawer L. L., Nathan C. F., Lowry S. F., Cerami A. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med. 1988 Feb 1;167(2):570–581. doi: 10.1084/jem.167.2.570. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES